From Casetext: Smarter Legal Research

In re Brand Name Prescription Drugs

United States District Court, N.D. Illinois, Eastern Division
Jan 10, 2001
94 C 897, MDL 997 (N.D. Ill. Jan. 10, 2001)

Opinion

94 C 897, MDL 997

January 10, 2001


MEMORANDUM OPINION


This matter is before the Court on the Manufacturer Defendants' motion for partial summary judgment and proposed order with respect to claims based on purchases made through wholesalers. For the reasons set forth below, Defendants' motion for partial summary judgment is granted in part and denied in part.

DISCUSSION

As a preliminary matter the Court reaffirms its oral statements to the effect that, under Illinois Brick Co. v. Illinois, 431 U.S. 720 (1977), plaintiffs cannot recover damages for purchases made through wholesalers on the theory that plaintiffs were overcharged for brand name prescription drugs in violation of Section 1 of the Sherman Act, 15 U.S.C. § 1. Nor can plaintiffs recover any damages for indirect purchases, however styled, if calculation of those damages would involve tracing a price hike through successive resales, or "incidence analysis." This is the law of the case as set forth by the Seventh Circuit in In Re Brand Name Prescription Drugs Antitrust Litigation, 123 F.3d 599, 605-606 (1997).

The Boies/Gravante Plaintiffs (the "Boies Plaintiffs") argue that they are entitled to seek "lost profits" damages on indirect purchases to the extent that their claims are based on a group boycott or conceded refusal to deal theory as opposed to an overcharge theory. The Seventh Circuit did state in dicta that the manufacturers' refusal to grant discounts to retail pharmacies, "if successfully challenged as a boycott," would fall "out of the orbit" of Illinois Brick. 123 F.3d at 606. Under such a claim, "Plaintiffs would be permitted to prove up whatever damages they could show had flowed from the boycott, provided they weren't seeking to recover overcharges, for that would entail the very incidence analysis that Illinois Brick bars." Id. The court did not reach the question of whether a group boycott claim would be successful on the facts of this case, however, because the class plaintiffs "ha[d] not cast their case in the boycott mold."

The Boies Plaintiffs contend that, unlike the class, they have challenged the manufacturers' refusal to grant them discounts as a group boycott or refusal to deal. They argue, therefore, that they should be entitled to recover lost profits flowing from the boycott. While the Boies Plaintiffs' complaints allegedly contain relevant counts and allegations, this Court has not examined their boycott or refusal to deal claims in any of the pretrial matters we have handled. We therefore take no position as to whether the Boies Plaintiffs can successfully demonstrate an unlawful boycott. We do caution, however, that any boycott damages that must be calculated through incidence analysis would, like the plaintiffs' overcharge claims, be barred by Illinois Brick.

The parties disagree as to whether the lost profits damages the Boies Plaintiffs seek necessarily entail the pass-on analyses proscribed byIllinois Brick. This is the type of fact-intensive evidentiary dispute that we have previously determined to be the province of the trial courts to which Plaintiffs' cases will soon return. We therefore limit our opinion to the preceding legal discussion.

CONCLUSION

For the foregoing reasons, Defendants' motion for partial summary judgment is granted insofar as it is consistent with the above stated legal principles.


Summaries of

In re Brand Name Prescription Drugs

United States District Court, N.D. Illinois, Eastern Division
Jan 10, 2001
94 C 897, MDL 997 (N.D. Ill. Jan. 10, 2001)
Case details for

In re Brand Name Prescription Drugs

Case Details

Full title:IN RE BRAND NAME PRESCRIPTION DRUGS ANTITRUST LITIGATION. This Document…

Court:United States District Court, N.D. Illinois, Eastern Division

Date published: Jan 10, 2001

Citations

94 C 897, MDL 997 (N.D. Ill. Jan. 10, 2001)